ATH 04
Alternative Names: AFFITOPE® AT04; AFFITOPE® AT04A+adjuvant; AT 04A; ATH-04; FB-6001Latest Information Update: 28 Jun 2024
At a glance
- Originator AFFiRiS
- Class Antihyperlipidaemics; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Cholesterol modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Hypercholesterolaemia(In volunteers) in Austria (SC, Injection)
- 14 Jul 2022 Frontier Biotechnology plans a clinical trial in Hypercholesterolaemia in China (Frontier Biotechnology website, July 2022).
- 22 Dec 2021 Affiris out-licenses ATH 04 to Frontier Biotechnologies in China, Hong Kong, Macau and Taiwan